HER2 positivity, in which the HER2 receptor is either overexpressed in the protein stage and/or amplified at the genomic level, has accounted for approximately 20% to 30% of breast cancers and 18% to 35% of mucinous EOCs.4–9. Here, ERBB2 is linked to breast carcinoma.